Therefore, in view of the obvious discrepancy in the expression of CYP2U1 in diverse molecular types of tumor specimens, the level of CYP2U1 may have a certain reference value in the selection of therapeutic regimen for breast cancer patients, and predicts that the patients with high CYP2U1 expression, have adverse clinical outcomes. The gene discussed is CYP2U1; the disease is neoplasm.